The purpose of the DIPAK cohort is to learn more about the disease course, to gather information on factors that influence disease severity, and how the disease affects quality of life. The DIPAK consortium is one of the research consortia started in the Netherlands with a grant from the Dutch Kidney Foundation (Nierstichting). It was founded in 2011 by four university medical centres (Groningen, Leiden, Nijmegen and Rotterdam).
Adult subjects affected by autosomal dominant polycystic kidney disease (ADPKD) as diagnosed by the revised Ravine-Pei criteria.
Please visit the UMCG Research Data Catalogue for more detailed information on our data and samples.
Data categories:
Sample categories:
Areas of information:
University Medical Center Groningen
Erasmus Medical Center Rotterdam
LUMC:
Other steering committee members are:
Prof. Tom Nijenhuis, dept. Nephrology, Radboud UMC Nijmegen
Prof. Joost Drenth, dept. Hepatology, Radboud UMC Nijmegen
Dr. Mahdi Saleh, dept. Nephrology, Erasmus UMC Rotterdam
Prof. Dorien Peters, dept. Human Genetics, Leiden UMC
Researchers attached to the DIPAK consortium have been instrumental in the discovery of the polycystic kidney and the polycystic liver disease genes. They discovered new elements of the pathophysiology of the disease by studying mice models, and risk markers for rapid disease progression. They were involved in writing several guidelines how to treat the disease. Lastly, a multidisciplinary protocol was developed how to treat chronic, incapacitating pain that many ADPKD patients suffer from.
University Medical Center Groningen (UMCG)
DIPAK
PO Box 30.001
9700 RB Groningen
The Netherlands
Visiting address
University Medical Center Groningen (UMCG)
Antonius Deusinglaan 1
9713 AV Groningen
